Cansu Akleylek

Cansu Akleylek

Auto-generated profile, based on publicly available information

Cansu Akleylek

Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine Trakya University Edirne Turkey

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2019 in Gynecological Endocrinology
Verified
Journal Article
Closed access
FTFiliz Tuna
Filiz Tuna
CACansu Akleylek
Cansu Akleylek
HÖHande Özdemir
Hande Özdemir
DKDerya Demirbağ Kabayel
Derya Demirbağ Kabayel
Pregnancy-associated osteoporosis (PAO) is a rare but painful disease. The current study aimed to investigate the demographic and clinical features, risk factors, treatment options, and outcomes of Turkish patients with PAO. In our retrospective, cross-sectional, and descriptive study the time to PAO diagnosis was 3.6 months. Pain and loss of height were detected in 78.6% and 28.6% of patients, respectively. As such, 60.6% of patients reported fractures at the thoracic area, 30.3% at the lumbar area, and 9.1% at the sacral area. While 14.3% of patients had optimal vitamin D status during pregnancy, 64.3% had vitamin D deficiency, and 21.4% had vitamin D insufficiency. Of the patients, 21.4% received anticoagulant therapy during their pregnancy. Dual X-ray absorptiometry scans revealed that osteoporosis was predominantly in the trabecular bone (L1–L4 Z-score –2.9, Femur Z score –2.19). Management options included supplements of calcium with vitamin D (93%), weaning the baby (79%), specific treatments for osteoporosis (64%), use of a supportive corset (50%), and exercise (21%), respectively. In addition, after delivery, 35.7% of patients were administered denosumab, 21.4% bisphosphonate, and 7.1% were given teriparatide. Data of the clinical features, treatments, and outcomes of PAO may contribute to early detection and management.

24 January 2022 in European Journal of Rheumatology
Verified
Journal Article
Open access
CACansu Akleylek
Cansu Akleylek
SOSeray Gizem Gur Ozcan
Seray Gizem Gur Ozcan
ISIbrahim Halil Sever
Ibrahim Halil Sever
SDSafiye Koçulu Demir
Safiye Koçulu Demir
ECEsin Cevik
Esin Cevik
NYNeslihan Yılmaz
Neslihan Yılmaz
Objective: Recommendations for the treatment of cytokine release syndrome/macrophage activation syndrome (MAS) associated with coronavirus disease-2019 (COVID-19) are still of poor quality. IL-6 is an important therapeutic target as a main mediator of cytokine storm. The aim of our study was to evaluate the tocilizumab (TCZ) efficacy and factors affecting the therapy outcome. Methods: This retrospective study included 27 patients treated with TCZ for COVID-19-MAS. All patients in this study were treated with TCZ (intravenously, at a dose of 8 mg kg1 ) in addition to standard therapy. Clinical improvement (survival and decreased oxygen demand) on the 10-14th days and secondary infection rate were assessed. Results: In our 27 treated patients, 14 (51.8%) received TCZ in the intensive care unit (ICU) and seven (25.9%) were need to invasive mechanical ventilation (IMV). Fifteen (55.6%) of these patients revealed a good clinical response (four patients discharge from the ICU and 11 patients who followed-up in nonICU beds showed a decrease in oxygen demand). TCZ was significantly less effective in patients having high Murray lung injury score, low PO2/FiO2 ratio, IMV, and ICU admission (P < .05). Severity of hypoxemia was found as a single independent risk factor in the multivariable analysis (P < .05). Secondary bacterial infections rate was significantly higher in intubated patients (P < .01) or treated in the ICU (P ¼ .01). Conclusion: TCZ was showed limited efficacy for COVID-19-related MAS. The most important predictive indicator for therapy outcome was found as the severity of hypoxemia. In addition, IMV and/or ICU was associated with the poor outcome and high side effect. So, controlled trials are still needed to confirm the indications and timing of TCZ therapy. Cite this article as: Akleylek C, Gür SG, Sever İH, et al. What are the main factors affecting the outcome of tocilizumab therapy in COVID-19-induced cytokine release syndrome? Eur J Rheumatol. 2022;9(3):126-131.


20 January 2025 in Thoracic Research and Practice
Verified
Journal Article
Open access
AKAbdulvahap Kahveci
Abdulvahap Kahveci
CACansu Akleylek
Cansu Akleylek
Sevilay BatıbaySevilay Batıbay
Sevilay Batıbay
Latent Tuberculosis Infection in Inflammatory Rheumatic Diseases Before Biological and Synthetic DMARD Treatment: Results from Three Rheumatology Centers in Different Regions of Türkiye - Thoracic Research and Practice

17 December 2025 in International Journal of Rheumatic Diseases
Verified
Journal Article
Closed access
HKHASAN KOCAAYAN
HASAN KOCAAYAN
EEElif Durak Ediboglu
Elif Durak Ediboglu
TYTuba Demirci Yıldırım
Tuba Demirci Yıldırım
BUBahar Ozdemir Ulusoy
Bahar Ozdemir Ulusoy
TOTahir Saygin Ogut
Tahir Saygin Ogut
SAServet Akar
Servet Akar

1 January 2024 in OSMANGAZİ JOURNAL OF MEDICINE
Verified
Journal Article
Closed access
CACansu Akleylek
Cansu Akleylek
FTFiliz Tuna
Filiz Tuna
HÖHande Özdemir
Hande Özdemir
YKYasemin Karal
Yasemin Karal
HTHakan Tuna
Hakan Tuna
The study aimed to investigate the results and early agreement of Prechtl analysis and cranial ultrasonography results in infants. In this cross-sectional retrospective study, we examined 64 babies who were born before 37 weeks gestational age with a birth weight under 2500 grams and were followed up between January 2015 and June 2017. We analyzed video footage taken during the weeks of the cases using Prechtl analysis to determine their movement patterns. We then compared the results of the motion analysis with the cranial ultrasonography examination results using Kappa test statistics to determine their compatibility. With the Prechtl analysis results, 57 (89.1%) of the cases were evaluated as 'normal general movements' and 7 (10.9%) as 'abnormal general movements'. While findings of pathology were detected as a result of cranial ultrasonography in 9 (14.1%) babies, no findings were observed in 55 (85.9%) babies. An 85.7% (kappa = 0.857) agreement was found between general movements results and cranial ultrasonography results. In risky babies with prematurity and low birth weight, early rehabilitation decisions as a result of general movements evaluation may contribute to reducing disability due to neurodevelopmental disorders.